More than 30 experts representing health plans, integrated delivery systems, health economists, providers, academicians, pharmaceutical manufacturers, and other professionals gathered for AMCP’s Partnership Forum to address the challenges in managing and providing timely access to rare and orphan disease therapies.
Read AMCP's summary of the Medicare Coverage of Innovative Technology proposed rule that would provide a national coverage pathway for breakthrough devices, including digital therapeutics.
AMCP submitted comments to the National Academies of Science, Engineering, and Medicine’s draft Preliminary Framework for COVID-19 Vaccine detailing our support to recognize pharmacists as front-line health care workers and pharmacies be included in the vaccine distribution and allocation plans.
AMCP signed on to joint comments on the National Academies of Science, Engineering, and Medicine’s draft Preliminary Framework for COVID-19 Vaccine, advocating for the inclusion of pharmacists as front line health care workers.
AMCP sent a letter to HHS Secretary Azar detailing our concerns with the recent Executive Order that would make changes to the anti-kickback statute safe harbor for manufacturer rebates and the potential for increased costs for patients.
AMCP signed on to a joint letter with other Medicare program stakeholders to HHS Secretary Azar detailing concerns with a recent Executive Order that would make changes to the anti-kickback safe harbor for manufacturer rebates and increase costs for patients.
AMCP joined with other national pharmacy stakeholders to thank HHS Secretary Azar for the agency's authorization of pharmacist administration of children's vaccines.
The leaders of 12 U.S. pharmacy organizations today issued the following statement celebrating the U.S. Department of Human Services order this week that expands the role of pharmacists in providing vaccines to children.
On August 4, 2020, CMS issued a request for information on implementation of requirements for electronic prescribing of controlled substances in Medicare Part D. Please send any feedback to advocacy@amcp.org by September 25.